Claire Fraser Sells 917 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Key Points

• Claire Fraser, a director at Becton, Dickinson and Company, sold 917 shares of the company's stock on September 10th, reducing her stake by 3.96% and leaving her with 22,226 shares valued at approximately $4.17 million.
• Becton, Dickinson reported strong quarterly earnings, with $3.68 EPS, exceeding analysts' estimates, and an annual revenue increase of 10.4% year-over-year.
• The company declared a quarterly dividend of $1.04 per share, reflecting a 2.2% yield, with a dividend payout ratio of approximately 74.82%.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Claire Fraser also recently made the following trade(s):

• On Friday, August 8th, Claire Fraser sold 863 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $192.30, for a total value of $165,954.90.

Becton, Dickinson and Company Stock Performance

BDX traded up $2.35 during trading on Thursday, reaching $190.78. The company's stock had a trading volume of 668,599 shares, compared to its average volume of 2,580,305. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company's fifty day moving average price is $185.95 and its 200-day moving average price is $192.31. The company has a market capitalization of $54.68 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the firm earned $3.50 EPS. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BDX shares. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Finally, Barclays cut their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $211.44.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Northcape Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC raised its stake in Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares during the period. Brady Family Wealth LLC raised its stake in Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after acquiring an additional 53 shares during the period. Diversified Trust Co raised its stake in Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 53 shares during the period. Finally, REAP Financial Group LLC raised its stake in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.